Moderna, Inc.
Moderna, Inc. (MRNA): 91 pipeline candidates · 2 upcoming catalysts · ~25 mo cash runway · 53 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.8 months
D/E 0.55 · 0% dilution
Lead: Phase 3
91 candidates
2 upcoming, next in ~42d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Moderna, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.5B
Cash
$1.9B
Quarterly Burn
$630.0M
Runway
24.8 mo
Revenue
$389.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (91 candidates)
| Drug | Phase |
|---|---|
| Adjuvanted Quadrivalent Influenza Vaccine | Phase 3 |
| Afluria® Quadrivalent | Phase 3 |
| COVID-19 Vaccine | Phase 4 |
| COVID-19 Vaccine 1 | Phase 4 |
| COVID-19 Vaccine 2 | Phase 4 |
| Cytomegalovirus vaccine | Phase 3 |
| Egg-based Quadrivalent Influenza Vaccine | Phase 3 |
| fluad | Phase 1 |
| FLUAD® | Phase 1 |
| Fluzone HD | Phase 3 |
Showing 10 of 91 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
732
Total value held
$17.86B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 45,744,916 | $2.32B |
| fmr llc | 45,672,024 | $2.32B |
| blackrock, inc. | 29,635,876 | $1.51B |
| vanguard portfolio management llc | 15,616,367 | $793.3M |
| state street corp | 14,861,409 | $755.0M |
| susquehanna international group, llp | 12,575,740 | $638.8M |
| geode capital management, llc | 9,435,132 | $478.5M |
| two sigma investments, lp | 9,207,004 | $467.7M |
| morgan stanley | 8,471,263 | $430.3M |
| ubs group ag | 8,337,033 | $423.5M |
Showing top 10 of 732 institutional holders of Moderna, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Moderna, Inc.'s pipeline?
Moderna, Inc. (MRNA) has 91 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Moderna, Inc.'s lead drug candidate?
Moderna, Inc.'s most advanced tracked candidate is Adjuvanted Quadrivalent Influenza Vaccine (Phase 3) for Influenza.
What is Moderna, Inc.'s next catalyst?
Moderna, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re" — expected July 30, 2026.
What is Moderna, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Moderna, Inc. has approximately 24.8 months of cash runway.
What is Moderna, Inc.'s market capitalization?
Moderna, Inc.'s market capitalization is approximately $23.5B.
Get the full picture on Moderna, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.